On May 15, Illumina announced that it has acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). More information at illumina.com/dragen.
Edico Genome is the leading secondary analysis solution provider for Next-Gen Sequencing, delivering its powerful DRAGEN Bio-IT Platform to clinical, research and genome centers around the globe. Leveraging field programmable gate array (FPGA) technology, DRAGEN delivers best-in-class accuracy, speeds, scalability and costs, enabling customers of all sizes to focus on what matters most – delivering breakthrough results. The comprehensive set of DRAGEN pipelines can be run onsite, in the Cloud or through a seamless hybrid cloud blend, allowing organizations to scale as their throughput fluctuates. Edico Genome has been awarded two GUINNESS WORLD RECORDSTM for its speed, and received top marks for its accuracy in the recent PrecisionFDA Challenge.